Article info
Hepatology
Original research
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
- Correspondence to Professor Jia-Horng Kao, Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taipei, Taiwan; kaojh{at}ntu.edu.tw
Citation
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
Publication history
- Received November 6, 2020
- Revised December 21, 2020
- Accepted December 23, 2020
- First published January 6, 2021.
Online issue publication
December 08, 2021
Article Versions
- Previous version (6 January 2021).
- Previous version (8 October 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.